Perz Jolanta, Topaly Julian, Fruehauf Stefan, Hensel Manfred, Ho Anthony D
Department of Internal Medicine V, University of Heidelberg, Germany.
Leuk Lymphoma. 2002 Jan;43(1):149-51. doi: 10.1080/10428190210178.
Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment.
利妥昔单抗（IDEC C2B8）是一种嵌合型人鼠单克隆抗CD20抗体，已被证明对治疗CD20阳性白血病和淋巴瘤患者有效。与其他B细胞淋巴瘤和正常B细胞相比，B细胞慢性淋巴细胞白血病（B-CLL）患者的CD20表达水平较低。先前对少数B-CLL患者使用利妥昔单抗治疗的经验表明，其在B-CLL中的疗效低于滤泡性淋巴瘤。我们分析了8例难治性或复发性B-CLL患者和2例B细胞幼淋巴细胞白血病（B-PLL）患者的CD20表达水平与利妥昔单抗治疗疗效之间的相关性。我们未能发现CD20表达与利妥昔单抗治疗疗效之间存在任何相关性。
